LOXO-260

N/A

Report date: 2025/05/09 15:53:45
NME

Base Information

Drug NameLOXO-260
Drug Alias NameLOXO-260LOX-19260LY-3838915
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And CompanyLoxo Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A